Ravidasvir: Phase III data

An open-label, Egyptian Phase III trial in 261 evaluable patients with chronic HCV genotype 4 infection showed that once-daily 200 mg oral ravidasvir plus Sovaldi sofosbuvir with or without ribavirin...